Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis.
about
Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune ComplexesPersonalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicabilityRate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databasesIndependent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory StudyImmunogenicity and PK/PD evaluation in biotherapeutic drug development: scientific considerations for bioanalytical methods and data analysis.The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents.Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuationEtanercept biosimilarsRheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only studyPredictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis.Immunogenicity of Isogenic IgG in Aggregates and Immune Complexes.Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.Antidrug antibodies in psoriasis: a systematic review.Diagnosing and treating psoriatic arthritis: an update.Etanercept: a review of its use in autoimmune inflammatory diseases.Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?Adverse reactions to biologic agents and their medical management.Systemic methotrexate for the treatment of psoriasis.Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes.Tumor necrosis factor-α (TNFα) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therapy.Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events.Golimumab for treatment of axial spondyloarthritis.Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases: The Missing Link.Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis.Impact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study.Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases.The Role of Aggregates of Therapeutic Protein Products in Immunogenicity: An Evaluation by Mathematical Modeling.Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health SystemRituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies.Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs.Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.Drug survival of tumor necrosis factor α inhibitors in patients with ankylosing spondylitis in Korea.Systematic reviews and meta-analyses on psoriasis: role of funding sources, conflict of interest and bibliometric indices as predictors of methodological quality.Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study.Effect of Thalidomide on Clinical Remission in Children and Adolescents with Ulcerative Colitis Refractory to Other ImmunosuppressivesPrimary versus secondary source of data in observational studies and heterogeneity in meta-analyses of drug effects: a survey of major medical journals
P2860
Q26766424-DAA5C424-DD9C-4F63-B53C-3A0A7382FB5BQ26771652-23D6F58C-AEEA-4400-99B2-5D40B5876039Q26778600-F23DA2B3-C900-43EF-BA88-1358B80CA0A0Q28551216-AD1FBB6A-A6FB-4137-9C2C-7F9D3ACE6712Q30716340-B1CD5E29-E882-4075-8DAB-844FD98DF8B3Q30995889-A257A11C-69DA-47EF-B207-C56F5001323FQ33726030-BD1DAB78-FBB8-416C-854E-275893117316Q34669637-D9C38238-B580-4B0D-BFB9-BABF799FE11AQ35020358-76E92177-6343-4AD8-BC84-15516728B6A6Q35544546-48F3390C-EA90-4E11-9CC7-36429694386BQ36182383-C82253D3-C32C-4CB4-A83D-3458BBAFA2B2Q36257660-4F74E247-6E0F-4AD7-A0C0-71C452E5FBDFQ36832755-8BC3E8C8-E22A-4F43-B912-7305B09A622DQ38151757-2898FCF9-A994-442D-B8BE-711FC5F6F9A5Q38165235-B135E57C-CC3B-4C8B-A9D6-FF1CD79ABB70Q38230740-1483CFCE-54F4-4E97-90E9-1F45537FBB28Q38238947-FD869ED7-824C-475E-9C1C-A331D0B1E8D9Q38238948-36904534-13B1-417D-8616-24303FBAB1DAQ38380882-A6B12061-1402-4ACF-972B-BE04F8E542B3Q38517691-A33D4BB9-9E75-49CB-9DAE-EFC2B634B046Q38611064-F6787B47-9F62-4A47-96ED-A4EA65E8C8BEQ38643965-9D4B8ACA-6DCE-4897-A12D-0294C4DC0FD2Q38707718-B6410CE6-214C-4781-8F4B-BD4589095187Q38826447-197BF9ED-FC02-46B9-BAA4-523379FEDC04Q38828876-F9538B9E-0270-45AC-95A7-6669784DAC37Q38920322-504C7DA4-1609-47C6-A4AF-EEAA73A7285FQ38972531-744DA624-EFC6-4B8F-AE1A-34B5D8E8167BQ41953123-225A567E-ECC6-41D0-8093-AC433E73AD11Q42734907-E7F32521-2A4A-4ED3-8457-105A53053D71Q45908921-B686225B-2051-4B83-B194-04C441534E75Q46172380-B27CE933-C0D1-4ECD-B7BA-1448BC5A9EE5Q47380976-8BE7D8FA-C367-4C0A-8930-F4223FC16320Q47983950-0C593787-1531-41DF-95CC-D8617134CFB0Q48246817-C4E9D1E0-9577-44FC-83DE-E305BBF633ECQ51627957-9BDE535A-8319-45C4-92D9-4CFD22177EA2Q57076619-6D25AFC3-A30E-42B6-8E94-505FB01CD888Q59128777-E89BB6AC-D6E1-4BB6-888A-7F96A0351842
P2860
Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Immunogenicity of monoclonal a ...... atic review and meta-analysis.
@ast
Immunogenicity of monoclonal a ...... atic review and meta-analysis.
@en
Immunogenicity of monoclonal a ...... atic review and meta-analysis.
@nl
type
label
Immunogenicity of monoclonal a ...... atic review and meta-analysis.
@ast
Immunogenicity of monoclonal a ...... atic review and meta-analysis.
@en
Immunogenicity of monoclonal a ...... atic review and meta-analysis.
@nl
prefLabel
Immunogenicity of monoclonal a ...... atic review and meta-analysis.
@ast
Immunogenicity of monoclonal a ...... atic review and meta-analysis.
@en
Immunogenicity of monoclonal a ...... atic review and meta-analysis.
@nl
P1476
Immunogenicity of monoclonal a ...... atic review and meta-analysis.
@en
P2093
Eva Salgado
Juan Jesus Gomez-Reino
P304
P356
10.1001/JAMAINTERNMED.2013.7430
P577
2013-08-01T00:00:00Z